Author

Nir Barzilai, MD

Holds the role of Professor in both Medicine and Genetics at Albert Einstein College of Medicine, where he also serves as the founding director of the Institute for Aging Research.

Nir Barzilai, MD

Author

At Albert Einstein College of Medicine, he is a Professor of Medicine and Genetics and the founding director of the Institute for Aging Research. He is the architect behind the TAME metformin trial.

Education and training

StageInstitution
MDEarned his degree from Technion, Israel Institute of Technology in 1985.
ResidencyYale University
Fellowship, MetabolismYale University
Completed a fellowship in Endocrinology and Molecular Medicine.Cornell

Current positions

  • Serves as Professor in the Department of Medicine (Endocrinology) and the Department of Genetics at Albert Einstein College of Medicine.
  • Holds the Ingeborg and Ira Leon Rennert Chair in Aging Research.
  • Serves as Founding Director of the Institute for Aging Research, also known as the Institute for Geroscience.
  • Directs the Nathan Shock Center of Excellence in the Basic Biology of Aging.
  • Directs the Paul F. Glenn Center for the Biology of Human Aging Research.
  • Director, Longevity Genes Project
  • Was elected President of the Global Academy for Health & Lifespan Research.

Research areas

His research spans geroscience, the genetics of exceptional longevity, metformin as an anti-aging intervention, nutritional and genetic effects on lifespan, the GH/IGF-1 axis, and metabolism in mammalian aging.

Key discoveries

The Longevity Genes Project encompasses over 600 centenarian families and has uncovered gene variants (CETP, APOC3, ADIPOQ, TSHR, IGF1R) linked to exceptional longevity and protection against cardiovascular disease, cancer, type 2 diabetes, and dementia.

TAME trial

He conceived and designed the TAME (Targeting Aging with Metformin) multicenter trial, which investigates whether metformin can delay the onset of multiple age-related conditions at once. The trial's strategic aim is to convince the FDA to consider aging itself as a treatable condition.

Book

Author of 'Age Later: Health Span, Life Span, and the New Science of Longevity'. (2020, St. Martin's Press)

Awards

His accolades include the Irving S. Wright Award of Distinction in Aging Research (2010), the IPSEN Longevity Award, the NIA Nathan Shock Award, the Beeson Award, the Paul Glenn Foundation Award, and the Senior Ellison Foundation Award. He is a Fellow of the Association of American Physicians and the New York Academy of Medicine.

Profiles and links

Retatrutide vial
Retatrutide 98%+ purity · third-party tested
$125.00